Sure. The gastric cancer incidence as a whole might be quite large. But the segment of those patients they are targeting for their Vaxx is very very small - only a tiny percentage of gastric cancer patients are eligible. And just before anyone jumps down my throat, I spoke with Imugene the other day and they agreed with that statement. Hence why the company is currently trying to sell it - which personally I dont think they will be able to because the results over chemo alone just were not good enough.
The lung cancer Vaxx is much more promising because NSCLC is a huge population. If they achieve success here with patients at the end of their treatment line, the share price will fly.
Ann: HER-Vaxx induced antibodies correlated with tumour reduction, page-155
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
-0.002(3.70%) |
Mkt cap ! $389.5M | |||
| Open | High | Low | Value | Volume |
| 5.4¢ | 5.4¢ | 5.2¢ | $129.6K | 2.456M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 37 | 3277804 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 608607 | 14 |
View Market Depth
| Last trade - 15.31pm 22/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |